Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Living near cyanobacterial blooms shortens survival in amyotrophic lateral sclerosis * Exposure to neurotoxic water sources ...

CAMBRIDGE, Mass., June 03, 2025--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS ...

The experimental ALS treatment usnoflast exhibited promising signs of slowed functional decline and improved breathing in a ...

The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

DAZALS trial missed its main goal, but patients on 300 mg dazucorilant had significantly improved survival at 24 weeks. ROSELLA trial met its endpoint, showing a 30% reduced risk of progression in ...

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic ...

About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig’s disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the ...

Brainstorm Cell Therapeutics plans to launch a Phase 3b trial to test NurOwn against a placebo in about 200 people with mild ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data. The biopharma revealed in ...

Living close to cyanobacterial harmful algal blooms - which are present nationwide but are more common in coastal and Great Lake states - heightens the rate of dying from amyotrophic lateral sclerosis ...